ADVERTISEMENT
2 /3 FREE ARTICLES LEFT THIS MONTH Remaining
Chemistry matters. Join us to get the news you need.

If you have an ACS member number, please enter it here so we can link this account to your membership. (optional)

ACS values your privacy. By submitting your information, you are gaining access to C&EN and subscribing to our weekly newsletter. We use the information you provide to make your reading experience better, and we will never sell your data to third party members.

ENJOY UNLIMITED ACCES TO C&EN

Outsourcing

Boehringer acquires oncolytic virus firm

by Ryan Cross
September 14, 2018 | APPEARED IN VOLUME 96, ISSUE 37

 

Boehringer Ingelheim will pay about $245 million to acquire the Austrian oncolytic viral therapy start-up ViraTherapeutics. The firm is developing a vesicular stomatitis virus that infects and replicates in cancer cells, causing the cells to burst and die. That causes inflammation in the tumor, which can help cancer immunotherapies, such as checkpoint inhibitors, work when they wouldn’t have otherwise. Earlier this year, Merck & Co. paid about $400 million for the oncolytic virus firm Viralytics, and Janssen Biotech acquired BeneVir for $140 million.

X

Article:

This article has been sent to the following recipient:

Leave A Comment

*Required to comment